Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDIL-2 + recMAGE-A3 + AS15 in Melanoma
NCT01266603Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2011
- Primary completion
- Nov 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recMAGE-A3 + AS15 in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2011; status: completed.
02
Drugs
recMAGE-A3 + AS15
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01266603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01266603.